Log in to search using one of your social media accounts:

 

Phase III data showed that Venclexta/Venclyxto plus MabThera/Rituxan helped people with previously treated chronic lymphocytic leukaemia live longer without their disease worsening compared to bendamustine plus MabThera/Rituxan
Roche announced today that the phase III MURANO study, which evaluated Venclexta ®/Venclyxto® (venetoclax) in combination with MabThera®/Rituxan® (rituximab) in people with relapsed or refractory chronic lymphocytic leukaemia (CLL), met its primary endpoint and showed a statistically significant improvement in the time people lived without their disease progressing (progress ion-free survival [PFS] as assessed by investigator) when treated with Venclexta/Venclyxto plus MabThera/Rituxan compared to bendamustine plus Mabthera/Rituxan. (Source: Roche Investor Update)
Source: Roche Investor Update - September 18, 2017 Category: Pharmaceuticals Source Type: news

Phase III data showed that Venclexta/Venclyxto plus MabThera/Rituxan helped people with previously treated chronic lymphocytic leukaemia live longer without their disease worsening compared to bendamustine plus MabThera/Rituxan
Roche announced today that the phase III MURANO study, which evaluated Venclexta ®/Venclyxto® (venetoclax) in combination with MabThera®/Rituxan® (rituximab) in people with relapsed or refractory chronic lymphocytic leukaemia (CLL), met its primary endpoint and showed a statistically significant improvement in the time people lived without their disease progressing (progress ion-free survival [PFS] as assessed by investigator) when treated with Venclexta/Venclyxto plus MabThera/Rituxan compared to bendamustine plus Mabthera/Rituxan. (Source: Roche Media News)
Source: Roche Media News - September 18, 2017 Category: Pharmaceuticals Source Type: news

Roche ’s polatuzumab vedotin receives priority medicines scheme (PRIME) designation for treatment of the most common form of aggressive lymphoma
Roche today announced that the European Medicines Agency (EMA) has granted PRIME (PRIority MEdicines) designation for the company ’s investigational medicine polatuzumab vedotin in combination with MabThera® (rituximab) and bendamustine for the treatment of people with relapsed or refractory diffuse large B cell lymphoma (DLBCL), the most common aggressive form of non-Hodgkin lymphoma. (Source: Roche Investor Update)
Source: Roche Investor Update - June 30, 2017 Category: Pharmaceuticals Source Type: news

Triplet Combo Active in Lenalidomide-Refractory Multiple Myeloma
Combining bendamustine, pomalidomide, and dexamethasone achieved a promising overall response rate in patients with heavily pretreated lenalidomide refractory multiple myeloma, according to the results of a phase I/II trial. (Source: CancerNetwork)
Source: CancerNetwork - June 20, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Hematologic Malignancies Multiple Myeloma News Source Type: news

Triplet Combo Active in Lenalidomide/Refractory Multiple Myeloma
Combining bendamustine, pomalidomide, and dexamethasone achieved a promising overall response rate in patients with heavily pretreated lenalidomide refractory multiple myeloma, according to the results of a phase I/II trial. (Source: CancerNetwork)
Source: CancerNetwork - June 20, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Hematologic Malignancies Multiple Myeloma News Source Type: news

Treanda (Bendamustine Hydrochloride Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - June 16, 2017 Category: Drugs & Pharmacology Source Type: news

MorphoSys initiates Phase III trial of MOR208 and bendamustine for DLBCL
German biotechnology firm MorphoSys has initiated patient enrolment for the Phase III part of the Phase II/III B-MIND clinical trial of MOR208 and bendamustine combination to treat diffuse large B-cell lymphoma (DLBCL). (Source: Drug Development Technology)
Source: Drug Development Technology - June 5, 2017 Category: Pharmaceuticals Source Type: news

Bendamustine Toxicity in FL Raises Eyebrows -- and Questions Bendamustine Toxicity in FL Raises Eyebrows -- and Questions
Results from the GALLIUM study in follicular lymphoma (FL) showed that fatal toxicity was higher with bendamustine compared with other regimens. What does this mean for clinical practice?Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 19, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Bendeka (Bendamustine Hydrochloride Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - July 6, 2016 Category: Drugs & Pharmacology Source Type: news

Roche's Gazyvaro approved in Europe in combination with bendamustine for people with previously treated follicular lymphoma
Roche announced today that the European Commission has approved Gazyvaro® (obinutuzumab) in combination with bendamustine chemotherapy followed by Gazyvaro maintenance in people with follicular lymphoma who did not respond or who progressed during or up to six months after treatment with MabThera® (rituximab) or a MabThera-containing regimen. (Source: Roche Media News)
Source: Roche Media News - June 16, 2016 Category: Pharmaceuticals Source Type: news

Roche's Gazyvaro approved in Europe in combination with bendamustine for people with previously treated follicular lymphoma
Roche announced today that the European Commission has approved Gazyvaro® (obinutuzumab) in combination with bendamustine chemotherapy followed by Gazyvaro maintenance in people with follicular lymphoma who did not respond or who progressed during or up to six months after treatment with MabThera® (rituximab) or a MabThera-containing regimen. (Source: Roche Investor Update)
Source: Roche Investor Update - June 16, 2016 Category: Pharmaceuticals Source Type: news

Response to 'Cure for Mantle Cell Lymphoma Within Reach'Response to 'Cure for Mantle Cell Lymphoma Within Reach'
Researchers not involved in the current research contest the characterization of bendamustine and rituximab as a "salvage" therapy, among other concerns. Letters to the Editor (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 10, 2016 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Rituximab Plus Bendamustine vs Standard Therapy for CLLRituximab Plus Bendamustine vs Standard Therapy for CLL
For patients with chronic lymphocytic leukemia (CLL), the combination of rituximab plus bendamustine was less effective than standard therapy, but it was also less toxic. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 27, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

First-line rituximab + bendamustine cost effective in advanced FL
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - April 30, 2016 Category: Drugs & Pharmacology Source Type: news

CHMP recommends EU approval of Roche’s Gazyvaro for people with previously treated follicular lymphoma
Roche announced today that the EU Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Gazyvaro® (obinutuzumab) in combination with bendamustine chemotherapy followed by Gazyvaro maintenance as a new treatment for people with follicular lymphoma who did not respond to, or who progressed during or up to six months after treatment with MabThera® (rituximab) or a MabThera-containing regimen. (Source: Roche Investor Update)
Source: Roche Investor Update - April 29, 2016 Category: Pharmaceuticals Source Type: news

CHMP recommends EU approval of Roche’s Gazyvaro for people with previously treated follicular lymphoma
Roche announced today that the EU Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Gazyvaro® (obinutuzumab) in combination with bendamustine chemotherapy followed by Gazyvaro maintenance as a new treatment for people with follicular lymphoma who did not respond to, or who progressed during or up to six months after treatment with MabThera® (rituximab) or a MabThera-containing regimen. (Source: Roche Media News)
Source: Roche Media News - April 29, 2016 Category: Pharmaceuticals Source Type: news

The U.S. Throws Out $3 Billion In Cancer Drugs Every Year
(Reuters Health) - U.S. doctors and hospitals throw out almost $3 billion (roughly 2.7 billion euros) in unused cancer drugs each year because the medicines come in supersized single-use packages and excess medicine must be discarded for safety reasons, a recent paper suggests. Researchers focused on 20 expensive medicines that are given by injection or intravenous drip and require doses adjusted based on the patient’s body size. Often, the packages contain much more medicine than patients need, and the leftovers wind up in the trash. Even when much of the medicine goes in the garbage, patients pay for the ...
Source: Science - The Huffington Post - March 28, 2016 Category: Science Source Type: news

FDA approves Roche’s Gazyva to treat follicular lymphoma
The US Food and Drug Administration (FDA) has granted approval for Roche's approved Gazyva (obinutuzumab) plus bendamustine chemotherapy, followed by Gazyva alone as a new treatment for people with follicular lymphoma. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - March 1, 2016 Category: Pharmaceuticals Source Type: news

FDA approves Roche's Gazyva (obinutuzumab) for certain people with previously treated follicular lymphoma
Roche today announced that the US Food and Drug Administration (FDA) approved Gazyva® (obinutuzumab) plus bendamustine chemotherapy followed by Gazyva alone as a new treatment for people with follicular lymphoma who did not respond to a Rituxan® (rituximab)-containing regimen, or had their follicular lymphoma return after such treatment. (Source: Roche Investor Update)
Source: Roche Investor Update - February 29, 2016 Category: Pharmaceuticals Source Type: news

FDA approves Roche's Gazyva (obinutuzumab) for certain people with previously treated follicular lymphoma
Roche today announced that the US Food and Drug Administration (FDA) approved Gazyva® (obinutuzumab) plus bendamustine chemotherapy followed by Gazyva alone as a new treatment for people with follicular lymphoma who did not respond to a Rituxan® (rituximab)-containing regimen, or had their follicular lymphoma return after such treatment. (Source: Roche Media News)
Source: Roche Media News - February 29, 2016 Category: Pharmaceuticals Source Type: news

FDA Okay for Obinutuzumab for Follicular LymphomaFDA Okay for Obinutuzumab for Follicular Lymphoma
The FDA has approved obinutuzumab to be used in combination with bendamustine as second-line treatment for follicular lymphoma. News Alerts (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 26, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

FDA Approves Genentech’s Gazyva (obinutuzumab) for Certain People with Previously Treated Follicular Lymphoma
South San Francisco, CA -- February 26, 2016 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved Gazyva (obinutuzumab) plus bendamustine chemotherapy... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - February 26, 2016 Category: Drugs & Pharmacology Source Type: news

Mundipharma EDO GmbH have entered into an agreement for the development and testing of a DRP ™ biomarker for Mundipharma EDO’s lead compound EDO-S101
Medical Prognosis Institute A/S (MPI.CO) (Denmark and Phoenix, AZ, USA) announced today that MPI and Mundipharma EDO GmbH have entered into an agreement for the development and testing of a DRP & trade; biomarker for Mundipharma EDO & rsquo;s lead compound EDO-S101 for the treatment of cancer. EDO-S101 is a first in class fusion molecule that combines two drugs & #39; mechanism of action in the cancer cell in order to increase the effect of treatment. MPI & #39;s specific DRP & trade; multiple biomarker for EDO-S101 is to identify those patients who have the highest likelihood of response to the c...
Source: Kidney Cancer Association - February 10, 2016 Category: Urology & Nephrology Source Type: news

Mundipharma EDO GmbH have entered into an agreement for the development and testing of a DRP™ biomarker for Mundipharma EDO’s lead compound EDO-S101
Medical Prognosis Institute A/S (MPI.CO) (Denmark and Phoenix, AZ, USA) announced today that MPI and Mundipharma EDO GmbH have entered into an agreement for the development and testing of a DRP™ biomarker for Mundipharma EDO’s lead compound EDO-S101 for the treatment of cancer. EDO-S101 is a first in class fusion molecule that combines two drugs' mechanism of action in the cancer cell in order to increase the effect of treatment. MPI's specific DRP™ multiple biomarker for EDO-S101 is to identify those patients who have the highest likelihood of response to the combination of bendamustine and v...
Source: Kidney Cancer Association - February 10, 2016 Category: Urology & Nephrology Source Type: news

Bendeka (Bendamustine Hydrochloride Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 16, 2015 Category: Drugs & Pharmacology Source Type: news

Teva, Eagle Cancer Drug Gets FDA Nod
FDA has approved BENDEKA injection -- a liquid, low-volume, 10-minute infusion formulation of bendamustine (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - December 9, 2015 Category: Pharmaceuticals Source Type: news

Idelalisib Trial Stopped Because of 'Overwhelming Efficacy'Idelalisib Trial Stopped Because of 'Overwhelming Efficacy'
In chronic lymphocytic leukemia, idelalisib combined with bendamustine and rituximab improved progression-free and overall survival compared with the standard two-drug combination. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 9, 2015 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Teva gets FDA approval for cancer drug
(Reuters) - Israel's Teva Pharmaceutical Industries said the U.S. Food and Drug Administration approved an injectable and infusion version of its cancer drug bendamustine. (Source: Reuters: Health)
Source: Reuters: Health - December 8, 2015 Category: Consumer Health News Tags: healthNews Source Type: news

AbbVie Submits IMBRUVICA(R) (ibrutinib) Phase III Combination Data to U.S. FDA
Phase III HELIOS (CLL3001) trial assessed the safety and efficacy of IMBRUVICA plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma NORTH CHICAGO, Ill., Nov. 13, 2015 -- (Healthc... Biopharmaceuticals, Oncology, FDAAbbVie, IMBRUVICA, ibrutinib, chronic lymphocytic leukemia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 13, 2015 Category: Pharmaceuticals Source Type: news

RBAC500 safe, effective for elderly patients with mantle cell lymphoma
Reducing the dose of cytarabine from 800 mg/m2 to 500 mg/m2 allowed a regimen of rituximab, bendamustine, and cytarabine to be safely administered as first-line therapy to elderly patients who had mantle cell lymphoma and were not candidates for autologous stem cell... (Source: Skin and Allergy News)
Source: Skin and Allergy News - July 8, 2015 Category: Dermatology Source Type: news

Roche’s Gazyva/Gazyvaro extended the time people with refractory indolent non-Hodgkin’s lymphoma lived without their disease worsening
Roche today announced results from the Phase III GADOLIN study showing that Gazyva/Gazyvaro (obinutuzumab) plus bendamustine followed by Gazyva/Gazyvaro alone provided significant benefit for people with indolent non-Hodgkin’s lymphoma (NHL) that is refractory to MabThera/Rituxan (rituximab)-based treatment (Source: Roche Investor Update)
Source: Roche Investor Update - May 30, 2015 Category: Pharmaceuticals Source Type: news

Roche’s Gazyva/Gazyvaro extended the time people with refractory indolent non-Hodgkin’s lymphoma lived without their disease worsening
Roche today announced results from the Phase III GADOLIN study showing that Gazyva/Gazyvaro (obinutuzumab) plus bendamustine followed by Gazyva/Gazyvaro alone provided significant benefit for people with indolent non-Hodgkin’s lymphoma (NHL) that is refractory to MabThera/Rituxan (rituximab)-based treatment (Source: Roche Media News)
Source: Roche Media News - May 30, 2015 Category: Pharmaceuticals Source Type: news

Targeted Drug with Chemotherapy Combo Offers Longer Life to Patients with B-cell Cancers
CHICAGO — Because of the significant benefit found in combining the targeted drug ibrutinib with standard chemotherapy for relapsed chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), an interim analysis has closed the international HELIOS phase III clinical trial. Led by Mayo Clinic, researchers found that ibrutinib and chemotherapy (bendamustine and rituximab, known as [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - May 30, 2015 Category: Databases & Libraries Source Type: news

Treanda (bendamustine hydrochloride) Solution by Teva: FDA Statement - Not Compatible with Closed System Transfer Devices, Adapters, and Syringes Containing Polycarbonate or Acrylonitrile-Butadiene-Styrene
Can lead to device failure, possible product contamination, and potential serious adverse health consequences. (Source: FDA MedWatch)
Source: FDA MedWatch - March 11, 2015 Category: American Health Source Type: news

Teva to commercialise Eagle's cancer drug in US
Israel-based Teva Pharmaceutical Industries has signed an exclusive licence agreement with Eagle Pharmaceuticals for its bendamustine hydrochloride (HCl) rapid infusion product. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - February 18, 2015 Category: Pharmaceuticals Source Type: news

Cornerstone begins Phase I trial of lymphoma drug candidate CPI-613
Cornerstone Pharmaceuticals has started a Phase I clinical trial of its lead drug candidate CPI-613, in combination with bendamustine (Treanda), to treat patients with relapsed or refractory classic Hodgkin's lymphoma (HL) or T-cell non-Hodgkin's lym… (Source: Drug Development Technology)
Source: Drug Development Technology - October 22, 2014 Category: Pharmaceuticals Source Type: news

GSK and Genmab receive European approval for Arzerra
GlaxoSmithKline (GSK) and Genmab have received European Commission marketing authorisation for Arzerra as first-line treatment for chronic lymphocytic leukaemia in combination with chlorambucil or bendamustine for patients ineligible for fludarabine-… (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - July 3, 2014 Category: Pharmaceuticals Source Type: news

Ofatumumab Now Has Full European Union Authorization for CLLOfatumumab Now Has Full European Union Authorization for CLL
The drug now has full European Union authorization for use in chronic lymphocytic leukemia (CLL) in combination with chlorambucil or bendamustine for patients ineligible for fludarabine-based therapy. International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 3, 2014 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

GSK and Genmab receive EU authorisation for Arzerra™ (ofatumumab) as first-line treatment for chronic lymphocytic leukaemia (CLL) in combination with chlorambucil or bendamustine for patients ineligible for fludarabine-based therapy
GlaxoSmithKline plc (LSE: GSK) and Genmab A/S (OMX: GEN) announced today that the European Commission (EC) has granted marketing authorisation for a new indication for the use of Arzerra™. (Source: GSK news)
Source: GSK news - July 3, 2014 Category: Pharmaceuticals Source Type: news

GSK and Genmab receive CHMP positive opinion for Arzerra (ofatumumab) in combination with chlorambucil or bendamustine as a first-line treatment for patients with chronic lymphocytic leukaemia (CLL) who are not eligible for fludarabine-based therapy
GlaxoSmithKline plc (LSE: GSK) and Genmab A/S (OMX: GEN) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending a variation to the terms of the marketing authorisation for Arzerra™ (ofatumumab) for a new indication in combination with chlorambucil or bendamustine for the treatment of patients with chronic lymphocytic leukaemia (CLL) who have not received prior therapy and who are not eligible for fludarabine-based therapy. (Source: GSK news)
Source: GSK news - May 23, 2014 Category: Pharmaceuticals Source Type: news

Study Finds New Chemo Combo May be Better for Some Non-Hodgkin’s...
Researchers say a combination of bendamustine and rituximab may be just as effective and less toxic than standard chemotherapy for indolent lymphomas.(PRWeb March 12, 2014)Read the full story at http://www.prweb.com/releases/2014/03/prweb11642851.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - March 13, 2014 Category: Pharmaceuticals Source Type: news

Glenmark faces patent infringement suit in US
Glenmark Pharmaceuticals has been slapped with a patent infringement case by US-based Cephalon Inc to sell generic version of Treanda. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - December 31, 2013 Category: Pharmaceuticals Source Type: news

Older Patients With CLL Receiving BendamustineOlder Patients With CLL Receiving Bendamustine
Find out more about the synergy of bendamustine and rituximab in chronic lymphocytic leukemia. Therapeutic Advances in Hematology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 26, 2013 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Genmab reports top-line results from Phase II CLL study of ofatumumab
Genmab has reported top-line results from a Phase II study of ofatumumab combined with bendamustine in untreated and relapsed chronic lymphocytic leukemia (CLL). (Source: Drug Development Technology)
Source: Drug Development Technology - May 1, 2013 Category: Pharmaceuticals Source Type: news

Bendamustine Plus Rituximab Boost PFS in Indolent LymphomasBendamustine Plus Rituximab Boost PFS in Indolent Lymphomas
The combination of bendamustine plus rituximab appears to be more effective and less toxic than standard therapy in indolent lymphomas. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 22, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Bendamustine (Levact®) Plus Rituximab More Effective Than CHOP-R In Treating Patients With Indolent Non-Hodgkin Lymphoma And Mantle Cell Lymphoma
Treatment with bendamustine plus rituximab (B-R) doubles progression free survival (PFS) compared with current standard of care CHOP-R (69.5 versus 31.2 months; p Results from the StiL NHL-1 study published in The Lancet this week show that a first-line treatment regimen of bendamustine plus rituximab (B-R) doubles progression-free survival (PFS) compared with the most often used treatment CHOP plus rituximab (CHOP-R), in newly diagnosed patients with indolent non-Hodgkin lymphoma (iNHL) and mantle cell lymphoma (MCL).1 Median PFS for patients treated with B-R was 69... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - February 22, 2013 Category: Consumer Health News Tags: Lymphoma / Leukemia / Myeloma Source Type: news

Bendamustine data published in The Lancet
Results from the StiL NHL-1 study published in The Lancet show that a first-line treatment regimen of bendamustine plus rituximab (B-R) doubles progression-free survival (PFS) compared with the most often used treatment CHOP plus rituximab (CHOP-R), in newly diagnosed patients with indolent non-Hodgkin lymphoma (iNHL) and mantle cell lymphoma (MCL). (Source: Pharmacy Europe)
Source: Pharmacy Europe - February 22, 2013 Category: Drugs & Pharmacology Source Type: news

RCT: Bendamustine plus rituximab vs CHOP plus rituximab as first-line treatment for indolent and mantle-cell lymphomas
Source: Lancet Area: News Rituximab plus chemotherapy, most often CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), is considered the first-line standard of care for patients with advanced indolent lymphoma, and for elderly patients with mantle-cell lymphoma, however there are no randomised comparative study data to show that this regimen is better than other chemotherapy regimens. Bendamustine plus rituximab is effective for relapsed or refractory disease and based on long-standing experience of its use in Germany, this prospective, randomised, open-label non-inferiority study compared this regimen with ...
Source: NeLM - News - February 20, 2013 Category: Drugs & Pharmacology Source Type: news

LCNDG Rapid Review: Bendamustine for relapsed follicular lymphoma refractory to rituximab
Source: London Cancer New Drugs Group Area: Evidence> Drug Specific Reviews The manufacturer of bendamustine (Napp Pharmaceuticals) was invited to submit evidence for a NICE single technology appraisal (STA) in May 2010. In June 2010, the manufacturer informed NICE that it would not be making an evidence submission because it was unable to identify comparative clinical evidence suitable for a NICE appraisal in people with rituximab refractory disease. The manufacturer indicated that further research was ongoing but data would not be available in a time frame that would allow NICE to produce timely guidance. NICE theref...
Source: NeLM - Drug Specific Reviews - February 15, 2013 Category: Drugs & Pharmacology Source Type: news